SCHEMBL29205158

SCHEMBL29205158

CCOC1CCN(C(=O)N2CCC(=C(C#N)c3ccc(F)cc3F)CC2)CC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACKR3 P25106 3/20 0.40
RAB9A P51151 2/20 0.38
DPP4 P27487 1/20 0.37
PROKR1 Q8TCW9 1/20 0.36
ALDH1A1 P00352 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
NPC1 O15118 1/20 0.35
GPR6 P46095 5/20 0.35
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
HTT P42858 1/20 0.34
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
KDM4E B2RXH2 1/20 0.34
FAAH O00519 1/20 0.34
MGLL Q99685 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27166113 0.89 USP30 (0.38) ACKR3RAB9APROKR1GPR6MAPK1
SCHEMBL29205135 0.86 LSS (0.40) ALDH1A1TDP1SMN1; SMN2KMT2AHTT
SCHEMBL27166026 0.84 PROKR1 (0.38) ACKR3RAB9ADPP4PROKR1MAPK1
SCHEMBL29205128 0.84 KMT2A (0.41) ACKR3RAB9ADPP4PROKR1NPC1
SCHEMBL27166045 0.84 RAB9A (0.40) ACKR3RAB9ADPP4PROKR1MAPK1
SCHEMBL27166079 0.79 PROKR1 (0.38) ACKR3RAB9ADPP4PROKR1ALDH1A1
SCHEMBL27166166 0.78 MEN1 (0.38) ACKR3RAB9ADPP4PROKR1ALDH1A1
SCHEMBL29205168 0.77 MCHR1 (0.40) DPP4ALDH1A1TDP1MGLL
SCHEMBL29205190 0.77 MGLL (0.40) MEN1KMT2AMGLL
SCHEMBL30055420 0.77 MGLL (0.40) MEN1KMT2AMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637471-B2 Heterocyclic compounds, compositions, methods of preparation and uses thereof ORGANON R&D FINLAND LTD. (FI) 2026-05-26 US disclosed
EP-4334289-B1 NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF Organon R&D Finland Oy (FI) 2025-06-25 EP disclosed
US-20240254131-A1 NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF ORGANON R&D FINLAND LTD. (FI) 2024-08-01 US disclosed
CN-117794899-A Novel heterocyclic compounds, compositions, methods of preparation and uses thereof 欧加农研发芬兰有限公司 2024-03-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254131-A1 NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF AKR1C3, AKR1C4, AKR1C1 ACKR3 801/4885RAB9A 4828/4885DPP4 2871/4885
US-12637471-B2 Heterocyclic compounds, compositions, methods of preparation and uses thereof AKR1C3, AKR1C4, AKR1C2 ACKR3 710/4885RAB9A 4551/4885DPP4 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.